Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.52 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (late primary spermatocytes) | 0.10 |
| chemistry Open Targets | compounds already reach it: zotiraciclib, alvocidib, rgb-286638 +9 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 12 Parkinson's papers of 7,144 | 0.66 |
| pathways Reactome | 36 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 0190
Sealed predictions
- CDK1 in dopamine neurons, braak+0.62 (p 0.073) → +0.20 (p 0.597)receipt 0196
Swarm cases
receipt 0196: CDK1 in dopamine neurons, braak
- power
- full sample +0.36 (p 0.145, n 18), 95% CI -0.13 to +0.71. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.36 (p 0.145, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.37 (p 0.132, n 18). could be the mix.
- skeptic
- leave-one-out range +0.29 to +0.53, sign flips 0; without severely affected donors +0.36 (p 0.145, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CDK1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts